Personalis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 07, 2023 at 04:12 pm EST
Share
Personalis, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 18.25 million compared to USD 14.86 million a year ago. Net loss was USD 29.1 million compared to USD 26.49 million a year ago. Basic loss per share from continuing operations was USD 0.6 compared to USD 0.58 a year ago. Diluted loss per share from continuing operations was USD 0.6 compared to USD 0.58 a year ago.
For the nine months, sales was USD 53.81 million compared to USD 48.33 million a year ago. Net loss was USD 81.71 million compared to USD 82.25 million a year ago. Basic loss per share from continuing operations was USD 1.71 compared to USD 1.81 a year ago. Diluted loss per share from continuing operations was USD 1.71 compared to USD 1.81 a year ago.
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Companyâs advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Companyâs tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.
PERSONALIS, INC. 
